Wockhardt Limited (IN:WOCKPHARMA)
:WOCKPHARMA
Want to see IN:WOCKPHARMA full AI Analyst Report?
WOCKPHARMA Stock Chart & Stats
₹1405.55
-₹25.55(-1.72%)
At close: 4:00 PM EST
₹1405.55
-₹25.55(-1.72%)
Day’s Range― - ―
52-Week Range₹1,086.80 - ₹2,420.00
Previous CloseN/A
Volume236.67K
Average Volume (3M)24.00K
Market Cap
₹319.88B
Enterprise Value₹349.92B
Total Cash (Recent Filing)₹9.30B
Total Debt (Recent Filing)₹24.56B
Price to Earnings (P/E)158.0
Beta1.41
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding162,485,570
10 Day Avg. Volume15,364
30 Day Avg. Volume24,000
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)3.86
Price to Sales (P/S)5.66
P/FCF Ratio298.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Recovery & Return To ProfitabilityA return to net profitability after multi-year losses, backed by ~12% top-line growth, reflects durable operational improvement. Sustained revenue growth and positive net income increase retained earnings, support reinvestment in manufacturing and R&D, and reduce solvency risk over the next 2–6 months.
Manageable Leverage & Stronger Equity BaseStable debt levels alongside a materially larger equity base improve balance-sheet cushioning. This enhances financial flexibility for capex, regulatory compliance, or working-capital needs and lowers refinancing strain, supporting durable operational continuity across business cycles.
Diversified Pharma Revenue StreamsA mixed business model—branded formulations, API supply and contract manufacturing—provides multiple durable cash-generation channels. Diversification reduces dependence on any single product or geography, smooths revenue volatility, and supports long-term market access and partner-driven growth.
Bears Say
Inconsistent Historical ProfitabilityRepeated prior losses and swinging EBIT indicate earnings are not yet structurally stable. This undermines predictability of cash flows, can constrain strategic investment, and raises the risk that one or two adverse quarters could restore loss-making, pressuring long-term financial resilience.
Uneven Cash Generation & Modest Free Cash FlowModest and volatile free cash flow limits internal funding for capex, debt reduction, or shareholder returns. Irregular cash conversion implies working-capital sensitivity and potential need for external financing during investment or regulatory compliance cycles, weakening balance-sheet reliability.
Regulatory & Approval-dependent OperationsRevenue and contract-manufacturing access depend on regulatory approvals and plant compliance. Delays, inspections or non-approvals can materially defer revenue recognition or limit market entry, creating persistent execution risk for product launches and manufacturing-led growth.
Wockhardt Limited News
WOCKPHARMA FAQ
What was Wockhardt Limited’s price range in the past 12 months?
Wockhardt Limited lowest stock price was ₹1086.80 and its highest was ₹2420.00 in the past 12 months.
What is Wockhardt Limited’s market cap?
Wockhardt Limited’s market cap is ₹319.88B.
When is Wockhardt Limited’s upcoming earnings report date?
Wockhardt Limited’s upcoming earnings report date is Aug 07, 2026 which is in 63 days.
How were Wockhardt Limited’s earnings last quarter?
Wockhardt Limited released its earnings results on May 04, 2026. The company reported ₹10.23 earnings per share for the quarter, beating the consensus estimate of N/A by ₹10.23.
Is Wockhardt Limited overvalued?
According to Wall Street analysts Wockhardt Limited’s price is currently Overvalued.
Does Wockhardt Limited pay dividends?
Wockhardt Limited pays a Notavailable dividend of ₹9.218 which represents an annual dividend yield of N/A. See more information on Wockhardt Limited dividends here
What is Wockhardt Limited’s EPS estimate?
Wockhardt Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wockhardt Limited have?
Wockhardt Limited has 162,485,570 shares outstanding.
What happened to Wockhardt Limited’s price movement after its last earnings report?
Wockhardt Limited reported an EPS of ₹10.23 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.216%.
Which hedge fund is a major shareholder of Wockhardt Limited?
Currently, no hedge funds are holding shares in IN:WOCKPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Wockhardt Limited
Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, the United Kingdom, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules. The company's biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. It also provides contract manufacturing services for sterile injectables, lyophilization, and other dosage forms; and research services. The company was founded in 1967 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.
Technical Analysis
Ajanta Pharma Limited
―
Alkem Laboratories Ltd.
―
Emcure Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―